FATE
FATE
NASDAQ · Biotechnology

Fate Therapeutics Inc

$1.19
+0.06 (+5.31%)
As of Mar 31, 3:11 PM ET ·
Financial Highlights (FY 2026)
Revenue
6.18M
Net Income
-126,851,064
Gross Margin
Profit Margin
-2,051.1%
Rev Growth
-59.0%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 63.6% 63.6%
Operating Margin -2,222.4% -2,000.2% -24.4% -27.5%
Profit Margin -2,051.1% -1,948.5% -25.6% -22.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 6.18M 15.06M 39.14M 43.52M
Gross Profit 24.91M 27.70M
Operating Income -137,336,253 -301,322,836 -9,536,619 -11,955,209
Net Income -126,851,064 -278,317,790 -10,010,485 -9,808,127
Gross Margin 63.6% 63.6%
Operating Margin -2,222.4% -2,000.2% -24.4% -27.5%
Profit Margin -2,051.1% -1,948.5% -25.6% -22.5%
Rev Growth -59.0% -59.0% +22.5% +8.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 13.35M 16.76M
Total Equity 48.97M 54.56M
D/E Ratio 0.27 0.31
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -125,358,699 -290,323,656 -16,322,152 -16,265,725
Free Cash Flow -10,981,777 -9,671,173